OSU Wexner Medical Center University Hospital
Welcome,         Profile    Billing    Logout  
 14 Trials 
32 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Muller, Carolyn Y
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Recruiting
3
230
US
Cisplatin, Platinol AQ, No treatment
GOG Foundation, GlaxoSmithKline
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
08/29
08/34
NRG-GY026, NCT05256225: Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer

Recruiting
2/3
525
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, High-Dose-Rate Vaginal Cuff Brachytherapy, HDR-VCB, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab and Trastuzumab hyaluronidase, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab/Hyaluronidase-oysk, Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20, Trastuzumab-Hyaluronidase-oysk
National Cancer Institute (NCI), NRG Oncology
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Carcinosarcoma
10/27
10/27
GOG-3026, NCT03673124: Ribociclib and Letrozole Treatment in Ovarian Cancer

Active, not recruiting
2
51
US
Ribociclib, Letrozole
Gynecologic Oncology Group, Novartis
Low Grade Serous Carcinoma
12/23
12/24
NCT05554328: Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recruiting
2
165
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate
National Cancer Institute (NCI), NRG Oncology
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
10/28
10/28
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
12/24
12/26
NRG-GY025, NCT05112601: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Recruiting
2
90
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
04/26
04/26
NIR-OGT-201, NCT05348356: Nirogacestat in Ovarian Granulosa Cell Tumors

Active, not recruiting
2
53
Europe, Canada, US
Nirogacestat, PF-03084014
SpringWorks Therapeutics, Inc.
Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer
07/26
12/27
NCT05554367: Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Recruiting
2
199
US
Binimetinib, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991
National Cancer Institute (NCI)
Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
08/26
08/26
NCT05903131: A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Recruiting
2
96
US
Telemedicine behavioral weight intervention, Progestin, Enhanced usual care, Levonorgestrel-releasing IUD.
Washington University School of Medicine, National Cancer Institute (NCI)
Endometrial Hyperplasia, Grade 1 Endometrial Cancer
10/28
10/29
KEYNOTE-B47, NCT04130516: Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Recruiting
1/2
200
US
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody, KEYTRUDA®, Pembrolizumab
Linnaeus Therapeutics, Inc., Merck Sharp & Dohme LLC
Solid Tumor, Adult
03/24
12/24
NRG-GY028, NCT05538897: Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recruiting
1/2
96
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Megestrol Acetate, 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate, 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione, 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone, 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone, BDH 1298, BDH-1298, Maygace, Megace, Megestat, Megestil, Niagestin, Ovaban, Pallace, SC 10363, SC-10363
National Cancer Institute (NCI), NRG Oncology
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
01/27
01/27
NCT05826015: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Withdrawn
1
36
NA
Paclitaxel, Taxol, Batiraxcept, AVB-500
Washington University School of Medicine, National Cancer Institute (NCI), Aravive, Inc.
Recurrent High Grade Uterine Cancer
06/29
06/34
NCT03943316: Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

Recruiting
N/A
100
US
New Mexico Cancer Care Alliance
Ovarian Cancer
12/25
12/27
NCT02470299: Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients

Active, not recruiting
N/A
21
US
Ketorolac, Toradol, Placebo
New Mexico Cancer Care Alliance
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
10/18
10/25
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
Canada, US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
Lim, Peter
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
ENGOT-EN17, NCT05712941: Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

Withdrawn
3
320
NA
Lerociclib, Letrozole 2.5mg, Placebo
EQRx International, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Endometrial Carcinoma
03/24
03/25
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
ENGOT-EN20, NCT05611931: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
ImmunoGen, Inc.
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
12/26
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
PRESERVE-004, NCT05446298: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Active, not recruiting
2
58
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, MK3475, Keytruda
OncoC4, Inc., Merck Sharp & Dohme LLC, GOG Foundation
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
06/25
06/26
GOG-3088, NCT05649956: Letrozole in Uterine Leiomyosarcoma

Recruiting
2
40
US
Letrozole
GOG Foundation
Uterine Leiomyosarcoma
07/28
07/29
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Silasi, Dan-Arin
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Nagel, Crista
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Myerscough, Callan
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29

Download Options